The Expression of miR-141 and mRNA PTEN with Cisplatin Therapy on NPC
DOI:
https://doi.org/10.18502/kls.v4i11.3853Abstract
The incidence of NPC in Yogyakarta province is 6.2/100 000 population and the tendency is increasing in the younger population. It has been known that drugs resistance also issues in NPC therapy. Cisplatin is drugs of choice that used in NPC therapy, besides miR-141 and mRNA PTEN are also had a role in chemotherapy
resistance in some of cancer. We conducted the examination of the expression of miR-141 from blood plasma pre and post-therapy patient and blood plasma in healthy control. The sample collected from whole blood and then plasma separation. RNA extracted using RNA Isolation Kit miRCURY-Biofluid, synthesis cDNA with cDNA
Synthesis kit. mRNA analysis with KAPA SYBR® FAST One-Step qRT-PCR Kit then detected by qRT-PCR. Data analysis with comparative analysis and statistical analysis. MiR-141 showed upregulation by 1.49 (p-value: 0.075) and mRNA PTEN showed downregulation by 0.65 (p-value: 0.323) in patients NPC compared to healthy control and there is a relationship between miR-141 and mRNA PTEN (p-value:0.001). The expression levels of miR-141 in patients pre- and post-therapy experience down-regulated (fold change:0.61, two-tailed t-test: 0.09) and mRNA expression levels of PTEN experience down-regulated (fold change:0.5, t-test two-tailed:0.09). The level expression of mRNA PTEN is still down-regulated through the expression of miR-141 is up-regulated indicated that the possibility of drugs resistance in therapy with cisplatin. Then, miR-141 is one of the important factors in cisplatin drugs resistance with inhibition of mRNA PTEN.
Keywords: miR-141, mRNA PTEN, Cisplatin, Drugs resistance, NPC.
References
Robbins SL, Kumar V. Buku ajar patologi I. [Basic pathology part I]. Penerbit Buku Kedokteran EGC. Jakarta; 2012. p.225. [in Bahasa Indonesia]. http://kink.onesearch. id/Record/IOS3737.SULUT000000000001352
Young LS, Dawson CW. Eipstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer 2014; 33(12):581. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308653/
Gan GS. Farmakologi dan terapi edisi 5. [Pharmacology and therapy 5
Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. [Review Article]. Journal of Nucleic Acid. 2010;2010:1–16. https://www.hindawi.com/ journals/jna/2010/201367/
Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 2016;76(13):3666. https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4930690/
Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, Wu M, et al. MicroRNA-141 is involved in a nasopharyngeal carcinoma related genes network. Carcinogenesis 2010;31(4):564. https://www.ncbi.nlm.nih.gov/pubmed/20053927
Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G. MicroRNA141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. 2011;56(4):270https://www.ncbi.nlm.nih.gov/ pubmed/21289630
Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32(36):4284. https://www.ncbi.nlm.nih.gov/pubmed/ 23045278.
Ching-Chuan K, Jang-Yang C, Yen-Ting C, Hung-Jie W, Wan-Shu L, Huang-Hui C, Chi-Yen C et al. Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia
(PA): AACR; Cancer Res 2011;71(8):1701. http://cancerres.aacrjournals.org/content/71/ 8_Supplement/1701
Vinciguerra M, Fabio C, Marion P, Sebastian C, Roberto M, Roberto B, Michelangelo F. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. Journal of Hepatology 2009;50:1139. https://www.ncbi.nlm.nih.gov/pubmed/19398230
Chalhoub N, Baker SJ. PTEN and the PI3-Kinase Pathway in Cancer. Annu Rev Pathol. 2009;4:127–150. https://www.ncbi.nlm.nih.gov/pubmed/18767981
Guo L, Su B, Wu Q, Yang S, Chen F. miRNA-miRNA interaction implicates for potential mutual regulatory pattern. Gene 2012:511(2):194. https://doi.org/10.1016/j.gene.2012. 09.066.
Alshalalfa M. MicroRNA response element-mediated miRNA-miRNA interactions in Prostate Cancer. Hindawi Publishing Corporation. Advances in Bioinformatics 2012: 2012:1–10 https://www.ncbi.nlm.nih.gov/pubmed/23193399
